This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.
Male patients aged 40 years or older
Diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO)
Initiating silodosin 8 mg/day therapy for the first time
Able to complete IPSS and IIEF-5 questionnaires
History of prior treatment with silodosin or other α-blockers in the last 3 months
Known neurogenic bladder or history of neurological disease affecting voiding
History of prostate surgery or pelvic radiation
Diagnosed prostate or bladder malignancy